The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Angiotensin-(1-7) Inhibits Vascular Smooth Muscle Cell Growth
Abstract
Although angiotensin II (Ang II) and the heptapeptide Ang-(1-7) differ by only one amino acid, the two peptides produce different responses in vascular smooth muscle cells. We previously showed that Ang II stimulated phosphoinositide hydrolysis, whereas Ang II and Ang-(1-7) released prostaglandins. We now report that Ang II and Ang-(1-7) differentially modulate rat aortic vascular smooth muscle cell growth. Ang-(1-7) inhibited [3 H]thymidine incorporation in response to stimulation by fetal bovine serum, platelet-derived growth factor, or Ang II. The reduction in serum-stimulated thymidine incorporation by Ang-(1-7) depended on the concentration of the heptapeptide over the range of 1 nmol/L to 1 μmol/L, with a maximal inhibition of 60% by 1 μmol/L Ang-(1-7). Ang-(1-7) also inhibited the serum-stimulated increase in cell number to a maximum of 77% by 1 μmol/L Ang-(1-7). The attenuation of serum-stimulated thymidine incorporation by Ang-(1-7) was unaffected by antagonists selective for angiotensin type 1 (AT 1) or type 2 (AT 2) receptors; however, [Sar 1,Ile 8]Ang II and [Sar 1,Thr 8]Ang II were effective antagonists, indicating that growth inhibition by Ang-(1-7) was a result of angiotensin receptor activation. In contrast, Ang II stimulated [3 H]thymidine incorporation in cultured vascular smooth muscle cells over the same concentration range, with a maximal stimulation of 314% at 1 μmol/L Ang II. Ang II also increased the total number of cells (to 145% of control), suggesting that enhanced thymidine incorporation was associated with vascular smooth muscle cell proliferation. The AT 1 antagonist losartan or L-158,809 but not AT 2 antagonists blocked [3 H]thymidine incorporation by Ang II. These results suggest that Ang-(1-7) and Ang II exhibit opposite effects on the regulation of vascular smooth muscle cell growth. The inhibition of proliferation by Ang-(1-7) appears to be mediated by a novel angiotensin receptor that is not inhibited by AT 1 or AT 2 receptor antagonists.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Emerging Concept of Vascular Remodeling
Epstein, F. H., Gibbons, G. H., & Dzau, V. J. (1994) · New England Journal of Medicine · doi:10.1056/nejm199405193302008 · Cited by 1,575
Inhibitors of Angiotensin-Converting Enzyme Prevent Myointimal Proliferation After Vascular Injury
Powell, J. S., Clozel, J.-P., Müller, R. K. M., Kuhn, H., Hefti, F., Hosang, M., & Baumgartner, H. R. (1989) · Science · doi:10.1126/science.2526370 · Cited by 1,052
Stoll, M., Steckelings, U. M., Paul, M., Bottari, S. P., Metzger, R., & Unger, T. (1995) · Journal of Clinical Investigation · doi:10.1172/jci117710 · Cited by 906
Angiotensin II induces smooth muscle cell proliferation in the normal and injured rat arterial wall.
Daemen, M. J., Lombardi, D. M., Bosman, F. T., & Schwartz, S. M. (1991) · Circulation Research · doi:10.1161/01.res.68.2.450 · Cited by 737
Nakajima, M., Hutchinson, H. G., Fujinaga, M., Hayashida, W., Morishita, R., Zhang, L., Horiuchi, M., Pratt, R. E., & Dzau, V. J. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.23.10663 · Cited by 680
Angiotensin-(1-7) Dilates Canine Coronary Arteries Through Kinins and Nitric Oxide
Brosnihan, K. B., Li, P., & Ferrario, C. M. (1996) · Hypertension · doi:10.1161/01.hyp.27.3.523 · Cited by 404
Self-citationPörsti, I., Bara, A. T., Busse, R., & Hecker, M. (1994) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1994.tb14787.x · Cited by 239
Antihypertensive actions of angiotensin-(1-7) in spontaneously hypertensive rats
Benter, I. F., Ferrario, C. M., Morris, M., & Diz, D. I. (1995) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.1995.269.1.h313 · Cited by 225
Self-citationCardiovascular actions of angiotensin(1–7)
Benter, I. F., Diz, D. I., & Ferrario, C. M. (1993) · Peptides · doi:10.1016/0196-9781(93)90097-z · Cited by 201
Self-citationMolecular mechanisms of vascular renin-angiotensin system in myointimal hyperplasia.
Dzau, V. J., Gibbons, G. H., & Pratt, R. E. (1991) · Hypertension · doi:10.1161/01.hyp.18.4_suppl.ii100 · Cited by 191
Cited by
The ACE2/angiotensin-(1-7)/MAS Axis of the renin-angiotensin system: focus on angiotensin-(1-7)
Santos, R. A. S., Sampaio, W. O., Alzamora, A. C., Motta-Santos, D., Alenina, N., Bader, M., & Campagnole-Santos, M. J. (2018) · Physiological Reviews · doi:10.1152/physrev.00023.2016 · Cited by 1,144
Counterregulatory Actions of Angiotensin-(1-7)
Ferrario, C. M., Chappell, M. C., Tallant, E. A., Brosnihan, K. B., & Diz, D. I. (1997) · Hypertension · doi:10.1161/01.hyp.30.3.535 · Cited by 509
Self-citationRecent advances in the angiotensin‐converting enzyme 2–angiotensin(1–7)–Mas axis
Santos, R. A. S., Ferreira, A. J., & Simões e Silva, A. C. (2008) · Experimental Physiology · doi:10.1113/expphysiol.2008.042002 · Cited by 432
Angiotensin-converting enzyme 2 and angiotensin 1–7: novel therapeutic targets
Jiang, F., Yang, J., Zhang, Y., Dong, M., Wang, S., Zhang, Q., Liu, F. F., Zhang, K., & Zhang, C. (2014) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2014.59 · Cited by 426
Angiotensin-(1-7) Dilates Canine Coronary Arteries Through Kinins and Nitric Oxide
Brosnihan, K. B., Li, P., & Ferrario, C. M. (1996) · Hypertension · doi:10.1161/01.hyp.27.3.523 · Cited by 404
Self-citationFerrario, C. M., Trask, A. J., & Jessup, J. A. (2005) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00618.2005 · Cited by 385
Self-citationSantos, R. A. S., Campagnole-Santos, M. J., & Andrade, S. P. (2000) · Regulatory Peptides · doi:10.1016/s0167-0115(00)00138-5 · Cited by 380
Angiotensin-(1–7) inhibits growth of cardiac myocytes through activation of the mas receptor
Tallant, E. A., Ferrario, C. M., & Gallagher, P. E. (2005) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00941.2004 · Cited by 318
Self-citationZisman, L. S., Keller, R. S., Weaver, B., Lin, Q., Speth, R., Bristow, M. R., & Canver, C. C. (2003) · Circulation · doi:10.1161/01.cir.0000094734.67990.99 · Cited by 308
The renin-angiotensin system and malignancy
Ager, E. I., Neo, J., & Christophi, C. (2008) · Carcinogenesis · doi:10.1093/carcin/bgn171 · Cited by 295
ACE2/ANG-(1–7)/Mas pathway in the brain: the axis of good
Xu, P., Sriramula, S., & Lazartigues, E. (2011) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00222.2010 · Cited by 283
Shenoy, V., Ferreira, A. J., Qi, Y., Fraga-Silva, R. A., Díez-Freire, C., Dooies, A., Jun, J. Y., Sriramula, S., Mariappan, N., Pourang, D., et al. (2010) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200912-1840oc · Cited by 281
Ocaranza, M. P., Godoy, I., Jalil, J. E., Varas, M., Collantes, P., Pinto, M., Roman, M., Ramirez, C., Copaja, M., Diaz-Araya, G., et al. (2006) · Hypertension · doi:10.1161/01.hyp.0000237862.94083.45 · Cited by 273
Castrop, H., Höcherl, K., Kurtz, A., Schweda, F., Todorov, V., & Wagner, C. (2010) · Physiological Reviews · doi:10.1152/physrev.00011.2009 · Cited by 269
Santos, R. A. (2014) · Hypertension · doi:10.1161/hypertensionaha.113.01274 · Cited by 259
Viana, G. E. N., Pereira, V. M., Honorato-Sampaio, K., Oliveira, C. A., Santos, R. A. S., & Reis, A. M. (2011) · Experimental Physiology · doi:10.1113/expphysiol.2011.058453 · Cited by 51
Barreta, M. H., Gasperin, B. G., Ferreira, R., Rovani, M., Pereira, G. R., Bohrer, R. C., de Oliveira, J. F., & Gonçalves, P. B. D. (2015) · Journal of the Renin-Angiotensin-Aldosterone System · doi:10.1177/1470320313491996 · Cited by 34
Metadata
- Authors
- Freeman, E. J., Chisolm, G. M., Ferrario, C. M., & Tallant, E. A.
- Venue
- Hypertension
- Published
- 1996-07
- Volume
- 28
- Issue
- 1
- Pages
- 104-108
- ISSN
- 0194-911X (ISSN-L)
- 1524-4563
- OpenAlex
- W2151166210
- Cited by
- 295
- References
- 30
- FWCI
- 8.96
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.